HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States
CONCLUSION: These real-world outcomes are consistent with ALCANZA results, demonstrating favorable outcomes with BV vs. OST in patients with CTCL previously treated with ≥1 systemic therapy.PMID:37919137 | DOI:10.1016/j.clml.2023.10.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 2, 2023 Category: Cancer & Oncology Authors: Stefan K Barta Nicholas Liu Maral DerSarkissian Rose Chang Mingchen Ye Mei Sheng Duh Andy Surinach Michelle Fanale Kristina S Yu Source Type: research
Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
J Comp Eff Res. 2023 Nov 2:e230073. doi: 10.57264/cer-2023-0073. Online ahead of print.ABSTRACTA decision analytic model was constructed to assess the cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy (O-B-O) in Chinese patients with relapsed and refractory follicular lymphoma (rrFL). O-B-O was associated with a dominant or more favorable cost-effectiveness than the conventional therapies. Survival outcomes, quality of life of progression-free survival, and subsequent treatment costs for progressive disease were the main drivers of the cost-effectiveness of O-B-O. The cost-ef...
Source: Journal of Comparative Effectiveness Research - November 2, 2023 Category: General Medicine Authors: Jun Ma Donglu Zhao Bihong Zhen Yan Xia Qianyi Gong Wendong Chen Source Type: research
